Creso Pharma

TSXV market listing anticipated to improve visibility of Cannara among the investor community

MONTREAL, April 7, 2021 – Cannara Biotech Inc. (“Cannara”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade indoor cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec, today announced its common shares will be listed on the TSX Venture Exchange (the “TSXV”). The common shares of the Company will commence trading on TSXV at the opening on Thursday, April 8, 2021. The Company is presently trading on the Canadian Stock Exchange (“CSE”). At the commencement of trading on the TSXV, the securities of the Company will be delisted from the CSE with no resulting change to the Company’s ticker (LOVE).

“The listing of our common shares on the TSX Venture Exchange is a significant milestone for Cannara,” said Zohar Krivorot, President and CEO of Cannara. “To begin trading on Canada’s leading venture exchange is a milestone achievement for which we are incredibly grateful.  We trust this momentum will continue to add value for our stakeholders as our business to grows.”

  Subscribe to news from
Cannara Biotech

Be the first to know when breaking news are released.

“The listing on the TSXV will generate increased investor awareness and will put the Company on the radar of major industry analysts,” said Nicholas Sosiak, Chief Financial Officer. “As the cannabis industry continues to expand and thrive both in Quebec and across Canada, investors are looking for companies with the expertise to lead the way. We at Cannara are excited and willing to assume that leadership.”

“2021 has been a year full of achievements for Cannara, and we’re only just getting started,” added Krivorot.

About Cannara Biotech Inc.

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is a vertically integrated producer of premium-grade indoor cannabis and cannabis-derivative products for the Quebec and Canadian markets. Its Quebec-based facility is one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec (625,000 square feet). Leveraging Quebec’s low electricity costs, the Cannara facility will produce purposefully cultivated indoor premium cannabis flower at an affordable price. For more information, please visit

The CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward-Looking” Information

This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Cannara Biotech Inc.

Cannara Biotech Commences Trading on TSXV on April 8, 2021

For further information: Nicholas Sosiak, Cannara Biotech, [email protected]; Zohar Krivorot, President & CEO, [email protected]

Related Links